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Abstract
Background: Studies in taxane and/or anthracycline refractory metastatic breast cancer (mBC) patients have shown
approximately 30 % response rates to irinotecan. Hence, a significant number of patients will experience irinotecan-
induced side effects without obtaining any benefit. The aim of this study was to lay the groundwork for
development of predictive biomarkers for irinotecan treatment in BC.
Methods: We established BC cell lines with acquired or de novo resistance to SN-38, by exposing the human BC
cell lines MCF-7 and MDA-MB-231 to either stepwise increasing concentrations over 6 months or an initial high
dose of SN-38 (the active metabolite of irinotecan), respectively. The resistant cell lines were analyzed for cross-
resistance to other anti-cancer drugs, global gene expression, growth rates, TOP1 and TOP2A gene copy numbers
and protein expression, and inhibition of the breast cancer resistance protein (ABCG2/BCRP) drug efflux pump.
Results: We found that the resistant cell lines showed 7–100 fold increased resistance to SN-38 but remained
sensitive to docetaxel and the non-camptothecin Top1 inhibitor LMP400. The resistant cell lines were characterized
by Top1 down-regulation, changed isoelectric points of Top1 and reduced growth rates. The gene and protein
expression of ABCG2/BCRP was up-regulated in the resistant sub-lines and functional assays revealed BCRP as a key
mediator of SN-38 resistance.
Conclusions: Based on our preclinical results, we suggest analyzing the predictive value of the BCRP in breast
cancer patients scheduled for irinotecan treatment. Moreover, LMP400 should be tested in a clinical setting in
breast cancer patients with resistance to irinotecan.
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Background
First-line chemotherapy of recurrent breast cancer (BC) is
dependent on the type of prior adjuvant treatment but it
most often consists of repeated cycles of anthracyclines
and/or taxanes, possibly combined with cyclophosphamide,
with standard combinations typically associated with
response rates of about 50–60 % [1]. Second-line treatment
may include 5-fluorouracil (5-FU), gemcitabine, or vinorel-
bine, and typically show response rates of 30–40 % [2].
Additional lines of treatment are also available in clinical
management of BC, but whenever a new line of treatment
is introduced patients show increasingly lower response
rates. Evidently, there is a critical need for more efficient
therapeutic intervention in metastatic breast cancer (mBC)
since many BC patients are exposed to chemotherapy, with
its ensuing side effects, without having any benefit from the
treatment. An improved therapeutic index (benefit/side
effect) may be achieved by identification of non-cross-
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resistant therapeutic options and/or by identification of
relevant predictive biomarkers to be used to identify
patients with the highest likelihood of benefit from a par-
ticular treatment.
Chemotherapeutic agents that target the Topoisomerase
I protein (Top1) are routinely used in treatment of meta-
static colorectal cancer [3] and have significant effect in
other cancer types as well, including glioblastoma multi-
forme, upper gastrointestinal cancers, pancreatic cancer,
ovarian cancer, small cell lung cancer and cervical cancer
[4]. Currently used Top1 targeting drugs, such as irino-
tecan, etirinotecan (NKTR-102), or topotecan are deriv-
atives of camptothecin. However, non-camptothecin
derived next generation Top1 inhibitors, such as inde-
noisoquinolines, are currently being tested in clinical
trials [4, 5] with promising results (http://clinicaltrials.-
gov/show/NCT01245192).
Irinotecan, etirinotecan and topotecan have also been
tested in clinical trials in mBC [6], and irinotecan and etir-
inotecan regimens were shown to benefit a considerable
proportion of mBC patients who had relapsed on prior
treatment with anthracyclines and taxanes [7, 8]. The
long-acting Top1 inhibitor etirinotecan has been evalu-
ated in a randomized phase III study; the BEACON study
[8, 9] . This study is based on data from a report that eval-
uated etirinotecan in 70 taxane-resistant mBC patients
and an objective response rate of 29 % was observed when
this drug was given as second- or third-line treatment [8].
These data was reproduced in the BEACON study, which
also demonstrated that etirinotecan was at least as effi-
cient as the physichian’s choice of treatment [9].
With expected objective response rates of approxi-
mately 25–30 % in pre-treated mBC patients, it is highly
likely that many of the patients developed cross-
resistance to Top1 inhibitors during their prior treat-
ment. For example, Top1 and Top2 inhibitors, and tax-
anes are all known substrates for xenobiotic drug
transporters from the ABC-cassette family, which may
be up-regulated during chemotherapy treatment [10].
Alternatively, resistance to Top1 inhibitors may be pre-
existing and could potentially also include resistance to
anthracyclines and taxanes, e.g., through up-regulation
of one or more common molecular drug resistance
mechanisms even before exposure to treatment.
Irrespective of the pre-existence or induction of resist-
ance, a validated molecular drug sensitivity/resistance
profile might enable physicians to identify patients who
are most likely to benefit from Top1 inhibitor treatment
and only offer this therapy option to these patients. Such
a strategy would increase the therapeutic index of Top1
inhibitors in mBC. In that respect, it has been shown
that around 30 % of BC patients possess amplifications
of the TOP1 gene [11] and a clinical trial is currently in-
vestigating if increased TOP1 gene copy numbers may
be a predictive biomarker for response to irinotecan in
BC patients [12]. However, no predictive biomarkers for
Top1 inhibitor treatment are implemented for clinical
use, meaning that the majority of mBC patients will ex-
perience drug-induced side effects without any thera-
peutic benefit. Moreover, there are unmet needs to
establish exactly when Top1 inhibitors should be used in
BC treatment, and to identify novel drug entities that
are effective in irinotecan-resistant BC.
With the aims to search for Top1 inhibitor predictive
molecular biomarkers and to identify which drugs are ef-
fective in irinotecan resistant BC cells, we have established
human breast cancer cell line model systems for resistance
to SN-38, the active metabolite of irinotecan. To cover a
wide range of potential mechanisms, we have established
four SN-38 resistant cell lines through exposure to either
gradually increasing concentrations of SN-38 or a single
high dose. We describe here potential molecular mecha-
nisms of SN-38 resistance in breast cancer cells and sensi-
tivity to other commonly used chemotherapeutic agents,
as well as novel non-camptothecin Top1 targeting drugs.
Methods
Chemicals and drugs
SN-38 and Ko143 (Sigma-Aldrich, Copenhagen, Denmark),
Epirubicin (2 mg/ml, Actavis Nordic A/S, Gentofte,
Denmark), Cisplatin (1 mg/ml, Hospira, Denmark) and
Docetaxel (20 mg/ml, Actavis Nordic A/S, Gentofte,
Denmark). The indenoisoquinoline drugs LMP776 (NSC
725776) and LMP400 (NSC 743400) [4, 5, 13], were pro-
vided by the NCI Developmental Therapeutics Program
(DTP), National Cancer Institute, NIH, Bethesda, MD,
USA. All drugs were dissolved in dimethyl sulfoxide
(DMSO) and stored at −20 °C. Drugs were dissolved in cul-
ture medium immediately before use.
Cell cultures
A panel of the 52 breast cancer cell lines was propagated in
complete media: RPMI 1640 (Gibco, Invitrogen, Denmark)
with 10 % fetal bovine serum (FBS, Gibco, Invitrogen,
Denmark) as previously described [14]. Docetaxel resistant
MCF-7 and MDA-MB-231 breast cancer cell lines were
grown as previously described [15].
Establishment of SN-38 resistant human breast cancer cell
lines
The human breast cancer cell line MDA-MB-231 was
obtained from American Type Culture Collection
(ATCC, Rockville, MD). Professor Ole William Petersen
(University of Copenhagen) kindly provided the human
MCF-7 breast cancer cell line. MCF-7 and MDA-MB-231
cell lines were maintained in DMEM including L-
glutamine medium (Gibco, Life Technologies, USA) sup-
plemented with 10 % FBS (Gibco Invitrogen, USA) for
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MDA-MB-231 cells and 5 % FBS, 1 % non-essential amino
acids (NEAA, Life Technologies, USA) for MCF-7 cells.
Cell lines were cultured in the presence of penicillin/
streptomycin antibiotics (100 U/mL, Invitrogen) and incu-
bated at 37 °C in a humidified environment containing
5 % CO2. SN-38-resistant and DMSO-exposed control cell
lines were maintained under the same medium condi-
tions, supplemented with SN-38 or DMSO, respectively.
All experiments were carried out in presence of SN-38
except for growth curves, cell cycle analysis and Top1 en-
zyme activity. The resistant cell lines were designated
“acq” for acquired resistance and “de novo” for de novo
resistance.
Initially, IC50 values for SN-38 were determined by
exposing cell lines to a range of SN-38 concentrations
using methylthiazolyldiphenyl-tetrazolium bromide
(MTT) assays to measure the response. To establish
acquired resistance, the parental cell lines were ex-
posed to SN-38 concentrations ranging from 5000- to
500-fold lower than IC50 and the highest concentration
that only caused minimal effect on the cells was chosen
as a starting point. The cell lines with acquired resist-
ance, MDAacq and MCF-7acq, were developed by ex-
posing the parental cell lines to stepwise increasing
concentrations of SN-38 (from 3.6nM – 68.2nM for
MDAacq and 3.0nM – 36nM for MCF-7acq) over
6 months. SN-38 exposed cell lines were maintained at
each drug concentration for three passages. Two resist-
ant cell lines were obtained after a total of 24 passages
for MDAacq and 23 passages for MCF-7acq in presence
of SN-38. To establish the de novo resistant cell lines we
initially exposed parental cell lines to SN-38 concentra-
tions ranging from the low nM range up to 25 μM and
selected the cell populations that eventually were able to
re-grow with constant exposure to SN-38. Thereby, we se-
lected de novo resistant cell lines, MDAde novo and MCF-
7de novo, which survived constant exposure to 24nM for
MDAde novo and 12nM for MCF-7de novo (Table 1). The
identity of both parental and resistant cell lines was con-
firmed by Short Tandem Repeat (STR) analysis (Identi
Cell, Aarhus, Denmark). In addition, all cell lines were
confirmed to be mycoplasma-free (Mycoplasma PCR
Detection Kit, Minerva Biolabs, Berlin, Germany).
Data mining of publicly available datasets
We extracted the IC50 values reported for topotecan [16]
and camptothecin [17] for the breast cancer cell lines
present in our panel of 52 cell lines and correlated the
IC50 values to the TOP1 copy numbers.
Cytotoxicity assay
In vitro drug resistance and cross-resistance were deter-
mined using the MTT and crystal violet assays as previ-
ously described [15]. Cell lines were plated for 48 h and
then exposed to drugs for 72 h. Using GraphPad Prism,
IC50 values of three independent repeats were calculated
to determine the change in resistance.
Cell growth and doubling time analysis
For the growth assay, 40,000 cells/well for MDA-MB-321
and 60,000 cells/well for MCF-7 were seeded in 6-well
plates. Cells were harvested at 24 h intervals for days 1 to 8.
The assay was conducted once and each well was counted
manually three times at each interval. Average values were
used to plot the growth curves. The doubling time of the
cells in exponential phase was calculated using the formula:
Doubling time = h∗ ln(2)/ln(c2/c1), where c1 and c2 repre-
sent the cell numbers at the beginning and end of the
exponential phase during time (h), respectively [18].
Cell cycle analysis by FACS
Fixation, propidium iodide staining and cell cycle ana-
lysis using fluorescence-activated cell sorting (FACS, BD
FACSVerseTM) and data analyses by FlowJo software
were done as previously described [19] and analyses
were repeated in two independent replicates.
Formalin fixation and paraffin embedding of cells
Cells were formalin fixed, embedded in agarose and par-
affin embedded as previously described [20].
FISH analysis
A TOP1/CEN-20 probe mix [20] and TOP2A FISH
pharmDx™ kit (Dako, Denmark, #K5333) were applied
according the manufactures instructions as previously
described [21]. This analysis was conducted once.
Table 1 Establishment of SN-38 resistant cell lines
Cell Lines SN-38 Dose Final SN-38
concentration
IC50 Values (μM) RR
Resistant cell lines DMSO control
MDAacq Stepwise (3.6nM-68.2nM) 68.2nM 40.2 ± 4.0 5.6 ± 0.9 7.2
MCF-7acq Stepwise (3.0nM-36nM) 36nM 33.6 ± 3.0 3.7 ± 0.5 9.1
MDAde novo Constant (24nM) 24nM 66.8 ± 16.2 0.7 ± 0.5 95.4
MCF-7de novo Constant (12nM) 12nM 31.9 ± 0.6 2.3 ± 0.9 13.9
Mean IC50-value (μM) ± standard deviation of three independent experiments. RR; relative resistance is the IC50-value of the resistant cell line divided by the IC50-value of
their corresponding DMSO controls
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Copy number data and mRNA microarray analysis on the
52 breast cancer cell lines
Gene expression dat obtained by Affymetrix U133
microarray (GEO entry GSE41313) were applied [14].
Copy number data were generated using SNP6 chips
from Affymetrix (Santa Clara, USA). Raw data were pre-
processed using Nexus software (BioDiscovery, Hawthorne,
USA) using the recommended settings for SNP calling, seg-
mentation and copy number status provided by Nexus
software.
mRNA microarray analysis on parental and the acquired
resistant cell lines
Total RNA was extracted from three independent pas-
sages of 70 % confluent cells for each of the four cell
lines (MCF-7 parental, MCF-7acq, MDA-MB-231 paren-
tal and MDAacq) using Trizol reagent (Invitrogen). Ex-
pression analysis using Agilent Human Gene Expression
Microarrays (G4845A, Agilent Techologies, Santa Clara,
CA, USA), image quality, background correction and
normalization were conducted as previously described
[22]. Sample clustering was performed by the ‘ward’
method in the software R (http://www.r-project.org/).
Statistical tests were performed using a moderated t-test,
and p-values were adjusted for multiple testing by the
Benjamin & Hochberg method [23]. Genes were consid-
ered significantly differentially expressed if the adjusted
p-value < 0.05 and the absolute log2-fold change > 0.8.
Gene Set Enrichment Analysis (GSEA) was performed
using the Clusterprofiler package [24] using Reactome,
KEGG and the GeneOntology data distributed Biocon-
ductor project. Network analysis was performed using
MetaCore from Thomson Reuters. Networks were con-
structed based on direct interactions in the MetaCore
database for all deregulated genes with a log2 fold
change > 1 and p-value < 0.05. For each cell line three
biological replicates were analyzed.
Availability of data and materials
The gene expression dataset supporting the conclusions
of this article is available in the ArrayExpress repository,
accession number E-MTAB-3224, https://www.ebi.ac.uk/
arrayexpress/experiments/E-MTAB-3224.
Protein purification, western blotting and Peggy analyses
Cells were grown to 70 % confluence and western blot-
ting was performed as previously described [22]. Primary
antibodies were incubated at 4 °C overnight (Top1
(Abcam, UK, 1:2000), Top2A (OriGene Technologies,
1:500), BCRP (Abcam, 1:1000), MDR1 (Novus biological.
Denmark, 1:1000) and β-actin (Sigma-Aldrich, Denmark,
1:15,000,000)). Species-specific horseradish peroxidase-
labeled secondary antibodies were applied for 1 h at 37 °C
(Anti-rabbit (Dako, Denmark): Top1 (1:10,000): and anti-
mouse (Dako, Denmark): BCRP (1:4000), MDR1 (1:5000),
β –actin (1:5000)). Protein bands were quantified using
ImageJ software. Three independent biological replicates
were analyzed for each cell line.
Peggy analysis was performed on a nanocapillary elec-
trophoresis analysis system (ProteinSimple, USA) for
size, amount and pI pattern of Top1 (28). For size ana-
lysis, cell lysates were diluted in MPER lysis buffer with
Bicine/CHAPS lysis buffer containing 2 % DMSO inhibi-
tors (ProteinSimple) and 4X master mix/fluorescent
standards (Protein Simple) according to the manufac-
turer’s instructions. The samples were denatured for
10 min at 70 °C and pipetted into a 384-well plate along
with primary antibodies (Top1 (Abcam) 1:100, β-actin
(Abcam) 1:100) diluted in Antibody Diluent Plus (Protein-
Simple) according to the manufacturer’s instructions. For
charge analysis, lysates were prepared in Bicine/CHAPS
lysis buffer containing 2 % DMSO inhibitors and diluted
with this and premix G2 pH 3–10 separation gradient
(ProteinSimple) containing 2.2 % ladder 1 (ProteinSimple).
Charge analysis samples were pipetted into a 384-well
plate along with primary antibodies (Top1 (Abcam)
1:50, β-actin (Abcam) 1:50) diluted in antibody diluent
(ProteinSimple) according to manufacturer’s instruc-
tions. Data were processed using Compass software
(ProteinSimple). The size analyses were repeated four
times with two independent biological replicates and
the charge analyses were conducted in biological
triplicates.
Top1 enzyme activity assay
The cellular Top1 enzyme activity was analyzed as previ-
ously described [25]. Briefly, cell lines were grown in the
absence of SN-38, trypsinized, counted, centrifuged and
1 million cells were pelleted for analyses in the presence
or absence of SN-38. Activity assays were conducted in
triplicate with three independent biological replicates.
BCRP drug-efflux pump inhibition
Cells were seeded at 10,000 cells/well in 96-well plates
and allowed to adhere for 48 h at 37 °C. Cell lines were
exposed to SN-38 with or without Ko143, a specific
BCRP inhibitor (Sigma Aldrich) for 72 h. Cell viability
was assessed using MTT assays with triplicate determi-
nations from three independent biological passages.
Statistics
MTT data were analyzed in Excel by two-tailed Student’s
T-test assuming equal variance and p-values below 0.05
was considered statistically significant. A non-parametric
test (Kruskall-Wallis) was used to associate the TOP1
copy number (CN)-status with mRNA expression levels
with the order of groups being CN loss, CN neutral and
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CN gain and a two-sided p-value below 0.05 was consid-
ered statistically significant.
Results
Topoisomerase 1 as predictor of response to SN-38
Increased TOP1 CN, Top1 mRNA or protein expression
or enzyme activity has been correlated to cancer cells’
sensitivity to Top1 targeting drugs [20, 26–29]. To fur-
ther explore this in breast cancer cells, we initially ap-
plied a FISH TOP1/CEN-20 probe mixture [20] to a
repository consisting of 52 human breast cancer cell
lines to analyze the distribution of TOP1 and CEN-20
CN and the TOP1/CEN-20 ratios in these cell lines
(Additional file 1: Figure S1a). The TOP1 CN varied from
1.2 (BT474) to 5.5 (HCC1419). There was a trend towards
association between TOP1 and CEN-20 copy numbers as
reflected in a TOP1/CEN-20 ratio close to 1 for the major-
ity of the cell lines (Additional file 1: Figure S1a). Compar-
ing FISH-derived TOP1 CNs to either SNP-derived CNs
or to TOP1 mRNA expression we found significant as-
sociations (p < 0.0001 and p = 0.0012, respectively) indi-
cating that the TOP1 genes are actively transcribed even
in cell lines with many TOP1 copies (Additional file 1:
Figure S1b,c). Based on the status of TOP1 CN, HER2
and estrogen receptors (ER), we then selected 9 breast
cancer cell lines from the panel of the 52 characterized
cell lines (Additional file 1: Figure S1d). In these se-
lected cell lines the Spearman’s correlation coefficient
between the TOP1 CN and gene expression levels was
0.64 (p = 0.067) and Top1 appeared to be functional be-
cause the cellular Top1 enzyme activity could be im-
paired by SN-38 (Additional file 1: Figure S2b). The
TOP1 CN corresponded well to the Top1 protein levels
observed in western blots, except for the HCC70 cell
line (Additional file 1: Figure S2a), and also correlated
significantly (r = 0,70, p = 0.035) to the Top1 enzyme ac-
tivity (data not shown). These 9 cell lines were then tested
for sensitivity to SN-38 (Additional file 1: Figure S2c) to
evaluate the correlation of TOP1 CN or TOP1 gene expres-
sion and sensitivity to SN-38. We found non-significant
negative Spearman’s correlation coefficients between the
IC50 values and the TOP1 CN (r = −0.20, p = 0.61) or
the TOP1 mRNA (r = −0.17, p = 0.64). However, the
Spearman’s correlation coefficients between the Top1
activity and the TOP1 CN or the TOP1 mRNA were (r =
0.65, p = 0.067) or (r = 0.95, p = 0.0004), respectively. This
indicates that more TOP1 copies and higher Top1 enzyme
activity correlate to increased sensitivity to SN-38.
We mined publicly available datasets to explore the cor-
relation between our TOP1 CN data to IC50 values re-
ported for topotecan [16] and camptothecin [17] in breast
cancer cell lines. In agreement with our data, the TOP1
CN had non-significant negative Spearman’s correlations
to the IC50 values for topotecan (r = −0.37, p = 0.087) and
for camptothecin (r = −0.24, p = 0.38). Thus, factors be-
yond TOP1 CN, Top1 expression and enzyme activity ap-
pear to be involved in the response to SN-38. Based on
the results presented above we selected two cell lines
to represent the majority of BC patients likely to be
candidates for Top1 targeted therapy, namely the
MDA-MB-231 and the MCF-7 cell lines, which repre-
sent cell lines with TOP1 CN gain (Additional file 1:
Figure S1a,d) and estrogen receptor/HER2 negative or
positive cells, respectively.
Establishment and characterization of resistant cell lines
The resistant model systems were established as de-
scribed in Materials and Methods (Table 1) and the re-
sistant phenotypes of the established cell lines were
initially confirmed by exposing the cell lines to their
final SN-38 concentration (68.2nM, 36nM, 24nM and
12nM, respectively, Additional file 1: Figure S3). These
MTT data confirmed significant increase in resistance
to SN-38 and the MDAacq MCF-7acq and MDAde novo
and MCF-7de novo cell lines were found to be 7, 9, 95
and 14-fold more resistant to SN-38, respectively,
when comparing the IC50 to their corresponding par-
ental and DMSO controls (Fig. 1, Table 1). Similar re-
sults were shown by crystal violet assay (data not
shown). The resistant phenotype was stable for all cell
lines as the resistance to SN-38 was retained after
withdrawal of SN-38 containing media for 1 month
(data not shown).
Growth curves
The growth curves (Additional file 1: Figure S4) illustrate
that the resistant cell lines had significantly (p < 0.05)
lower growth rates when compared to their parental and
DMSO controls (all cell lines were grown in the absence
of SN-38). The doubling times of MDAacq, MCF-7acq,
MDAde novo and MCF-7de novo were 35.5, 44.3, 43.9 and
33.2 h, respectively, which was 7.8, 11.7, 16.8 and 6.1 h
longer than their respective DMSO controls. The increase
in doubling times was significant (p < 0.05) for all cell lines
except for MCF-7de novo (p = 0.08).
Cell-cycle distribution
Cell cycle analyses were performed without adding SN-38
to investigate the reason for longer doubling time of the
resistant cell lines, and the results showed that the resist-
ant cell lines had increased percentage of cells in G2/M
phase and decreased percentage of cells in G0/G1 phase
in comparison to their parental controls (Additional file 1:
Figure S5), which indicated cell cycle arrest at the G2/M
phase as a factor for increased doubling time of the resist-
ant cell lines.
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Cross-resistance to other anti-cancer drugs
The SN-38 resistant cell lines were assessed for cross-
resistance to a range of anticancer drugs (cisplatin, do-
cetaxel, epirubicin, LMP400 and LMP776) in compari-
son to their DMSO controls. Resistant cell lines
exhibited different and complex patterns of cross-
resistance to various anti-cancer drugs, which is sum-
marized in Table 2. Most strikingly, a consistent pattern
was observed with docetaxel as none of the SN-38 resistant
cell lines had developed cross-resistance to this drug. Inter-
estingly, the docetaxel resistant MCF-7 and MDA-MB-231
cell lines were cross-resistant to SN-38 (Additional file 1:
Figure S6). For epirubicin, both MDAacq and MDAde novo
showed cross-resistance whereas the MCF-7acq and MCF-
7de novo remained sensitive. For the indenoisoquinoline
Top1-targeting drug LMP776, which is a weak substrate
for BCRP, three out of four cell lines showed cross-
resistance, whereas three out of four SN-38 resistant cell
lines remained sensitive to LMP400 (NSC 724998), which
is not a BCRP substrate [5]. For cisplatin, the cross-
resistance pattern was complex and two out of four cell
lines demonstrated cross-resistance (Table 2).
Fig. 1 Sensitivity to SN-38 in the established SN-38 resistant cell lines in comparison to their controls. Using MTT assay, cells were exposed to the shown
SN-38 concentrations for 72 h. Triplicate wells were analyzed, and data shown is mean ± s.d. of a representative experiment in percentage. n= 3
Table 2 Drug sensitivity IC50-values and Relative resistance
Anti- cancer drugs Epirubicin RR Docetaxel RR Cisplatin RR LMP776 RR LMP400 RR
MDAacq DMSO 0.4 ± 0.2 4.3 22.0 ± 9.9 1.0 62.8 ± 13.7 1.1 8.9 ± 11.7 5.0 10.5 ± 9.7 1.2
MDAacq 1.7 ± 0.3 21.0 ± 5.3 70.6 ± 4.1 44.6 ± 45.7 12.4 ± 12.2
MCF-7acq DMSO 0.9 ± 0.5 1.9 20.4 ± 2.3 1.3 26.1 ± 9.5 2.5
a a
MCF-7acq 1.7 ± 0.9 25.8 ± 8.2 65.6 ± 53.4
a a
MDAde novo DMSO 5.2 ± 3.2 3.4 18.0 ± 3.7 1.5 34.7 ± 7.03 2.7 11.0 ± 6.2 2.0 15.8 ± 6.3 1.6
MDAde novo 17.6 ± 1.4 27.3 ± 2.1 95.1 ± 4.9 22.5 ± 4.3 25.8 ± 3.5
MCF-7de novo DMSO 8.1 ± 9.1 1.2 24 ± 7.5 1.5 45.6 ± 5.4 1.2 40.0 ± 14.2 1.4 42.6 ± 36.3 1.4
MCF-7de novo 10.0 ± 7.9 34.9 ± 10.2 53.7 ± 13.0 55.9 ± 28.6 58.2 ± 36.5
Mean IC50-value (μM) ± standard deviation of three independent experiments. RR; relative resistance is the IC50-value of the resistant cell line divided by the IC50-value of
their corresponding DMSO controls aCross-resistance by looking at the graphs as 50 % inhibition was not achieved with these drugs
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Florescence in-situ hybridization (FISH)
To investigate whether the acquired resistance to SN-38
correlated to aberrations in TOP1 or TOP2A at the gene
level, FISH analysis was performed on parental, MDAacq
and MCF-7acq cell lines. No differences in the TOP1 or
TOP2A CN between the resistant cell lines and the re-
spective control cell lines were detected. Furthermore,
neither TOP1/CEN-20 nor TOP2A/CEN-17 ratio num-
bers were different among the respective cell lines
(Additional file 1: Table S1).
Gene expression analysis
Genome-wide gene expression analyses on the DMSO
control and the two SN-38 acquired resistant cell lines
identified differentially expressed genes, which are visu-
alized with a heatmap (Fig. 2a). The MCF-7 cells and
MDA-MB-231 cell lines clustered separately; however,
resistant cell lines did not cluster separately from DMSO
controls (Additional file 1: Figure S7b). The MDAacq
model system had numerous differentially expressed
genes, 32 of these genes being differentially expressed in
common to both the MDA and the MCF model systems
(Additional file 1: Figure S7b and Additional file 2).
The ABCG2 transcript, encoding the breast cancer re-
sistance protein (BCRP), was the most up-regulated in the
MDAacq system (32 fold up-regulation) and the second
most deregulated in the MCF-7acq system (4 fold up-
regulation) (Additional files 3 and 4). Only one other gene
in the top 50 was deregulated in common, namely ID3
(inhibitor of DNA binding 3), which was 4 fold up-
regulated in both MDAacq and MCF-7acq. It is of interest
to note that the ABCB1 transcript, encoding the
permeability-glycoprotein (Pgp/MDR1) was not deregu-
lated in the acquired resistance cell lines. Gene Ontology
(GO) Molecular Function analysis found that the most
prominent common GO term was the category “tran-
scription cofactor activity”, defined by genes that inter-
act selectively and non-covalently with a regulatory
transcription factor and also with the basal transcription
machinery in order to modulate transcription. Reactome
and KEGG pathway analyses identified among the top
10 pathways “Metabolism of xenobiotics by cytochrome
Fig. 2 Global expression analysis of resistant (res) and non-resistant DMSO control cell lines (wild type, wt). a Heatmap showing differentially expressed
genes (see text), the rows are genes, columns samples and the colors show the normalized expression level, yellow being high expression and blue
low. b, c, d MetaCore analyses of networks among genes differentially expressed in the resistant cells. In MCF-7acq two networks were identified (b, c)
and in the MDAacq a single netwwotk was indetified (d). Network formation was established based on known direct interactions
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P450”, “Nucleosome assembly” and “DNA damage/
Telomere stress induced senescence” (data not shown).
In the MCF-7acq the MetaCore network analysis of the
deregulated genes highlighted two networks of 19 and
10 genes with the most connecting nodes being the
transcription factors PR and FUS/DDIT3, the kinase in-
hibitor p21 and the regulatory protein RIP140 (Fig. 2b,c).
In the MDAacq cells a network of 94 genes was
highlighted and the most connecting nodes being the
transcription factors HNF3 and PAX8, as well as the pro-
tease BACE1 and the kinase inhibitor p21 (Fig. 2d). These
nodes might represent important causative changes for
the development of resistance in the model system.
Differential protein expression in SN-38 resistant cell lines
The expression of proteins previously suggested to be in-
volved in resistance to SN-38 (Top1, Top2a, BCRP and
MDR1) was evaluated by Western blotting (Fig. 3 and
Additional file 1: Figure S8). The levels of Top1 were
markedly reduced (<50 %) in MDAacq, MCF-7acq and
MDAde novo cell lines while only a minor decrease in
Top1 protein expression was seen in MCF-7de novo.
Top2a levels remained unchanged in all resistant cell
lines (Additional file 1: Figure S8). A clearly increased
protein expression of the drug efflux pumps MDR1 and
BCRP was observed in the MDAacq cell line. Likewise,
MDAde novo had a strong BCRP over- expression; how-
ever, it had only a minor increase in MDR1 expression.
A minor increase in expression of BCRP was observed
in MCF-7acq and MCF-7de novo while no expression of
MDR1 was detected in any of the MCF-7 cell lines.
We applied nanocapillary electrophoresis for more pre-
cise quantification of the Top1 protein. Top1 and β-actin
were simultaneously detected and fully separated without
background signals (Additional file 1: Figure S9). The
Top1 signals were normalized by the β-actin signals and
compared between resistant and DMSO control cell lines
(Fig. 3d). This showed significant (p < 0.05) down regula-
tion of Top1 in MDAacq (0.55x), MCF-7acq (0.35x) and
MDAde novo (0.12x) whereas the MCF-7de novo showed a
slight increase (1.5x). Post translational modifications
(PTMs) of Top1 have been associated with sensitivity to
Top1 targeting drugs [18, 30] and we therefore analyzed
the Top1 isoelectric patterns in the cell lines (Fig. 3e).
Overall, the Top1 pI charge profiles were alike in the
MCF-7 and MDA-MB-231 DMSO controls with
Fig. 3 Western blotting of total protein extracts from SN-38 resistant (R) in comparison to their respective controls (Parental (P) and DMSO
(D)). All samples were immunoblotted with an antibody to β-actin to illustrate equal protein loading (a): Western blotting of Top1/β-actin;
(b): BCRP/β-actin; (c): MDR1/β-actin. Protein bands were quantified by image J software. Number represents relative intensity (RI) bands to
their respective DMSO control. d Top1 and β-actin proteins signals from nanocapillary electrophoresis were quantified and expressed in percent of the
relevant DMSO control cell lines. All differences were signicant (p < 0.05) with p-values of 0.0088, 0.00012, 0.0017 and 0.00018 for MDAacq, MCF-7acq,
MDAde novo and MCF-7de novo, respectively. e Visualization of the Top1 isoelectric patterns in the cell lines MCF-7acqDMSO, MCF-7acq (top panel) and
MDAacqDMSO, MDAacq (lower panel)
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prominent peak signals in the area around 5.5 and 7.5-8.5.
When MCF-7acq cells were compared to MCF-7 control
cells the pI peak pattern was very similar to the MCF-7
DMSO controls indicating no major changes in Top1
PTMs in the resistant MCF-7 cells. However, the MDAacq
cells lost the peak signals in the pI range around 5.5 and
7.5-8.5 but gained peak signals around pI 5 and pI 6.4.
These data indicates that Top1 PTMs are changed in the
MDAacq cells.
Inhibition of BCRP drug-efflux pump
To investigate the functional importance of the ob-
served up-regulation of the BCRP pump in SN-38 re-
sistance in breast cancer cells, we inhibited its activity
using Ko143, a specific inhibitor of this pump [31, 32].
The Ko143 compound did not have any effect on cell
survival and did not interfere with the effect of SN-38
on the DMSO control cell lines. Co-treatment with
Ko143 and SN-38 resulted in significant (p < 0.05) and
complete re-sensitization of the MDAacq, MDAde novo and
MCF-7de novo cell lines to the level of DMSO control cell
line. Although significant (p = 0.01) the MCF-7acq was
only slightly re-sensitized to SN-38 following Ko143 co-
treatment (Fig. 4).
Discussion
Resistance to treatment is a major obstacle in the
current management of BC patients. As response rates
to Top1 inhibitors in mBC is around 30 % [6, 8] it is
clear that the majority of patienst are or become resist-
ant. In order to develop novel non-cross-resistant agents
and to identify predictive molecular markers, a more de-
tailed insight into the underlying molecular mechanisms
of drug resistance is necessary. Although the occurrence
of resistance to camptothecins is not understood in de-
tail, it is thought to be mediated by multiple mecha-
nisms, including, but not limited to, reduced drug-target
interactions, down-regulation of the Top1 enzyme,
TOP1 gene mutations and increased drug efflux, result-
ing from up-regulated expression of efflux drug trans-
porters [4, 33, 34]. We report here the first preclinical
model system of SN-38 drug resistance in BC. After test-
ing 52 human BC cell lines, we selected two lines based
on SN-38 sensitivity, TOP1 gene copy status, HER2
Fig. 4 Inhibition of the BCRP efflux pump in SN-38 resistant cell lines in comparison to their controls in MTT assay. Cells were exposed to their
corresponding final SN-38 concentration with or without Ko143 (5 μM) for 72 h. Triplicate wells were analyzed, and data shown is mean ± s.d. of
a representative experiment in percent of untreated cells (controls), n = 3. The p-values between SN-38 treated and SN-38 + 5 μM inhibitor were
all below 0.05 (the p-values for MDAacq, MCF-7acq, MDAde novo and MCF-7de novo were 9.6E-5, 0.01, 7.2E-5 and 0.0001, respectively)
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status and estrogen receptor protein expression, and
used these two cell lines to develop SN-38 resistance by
either exposing them to stepwise increasing concentra-
tions of SN-38 over a period of 6 months or by selecting
the cell population that survived exposure to the highest
SN-38 concentration.
Some common traits were identified in the SN-38 re-
sistance mechanisms of all four SN-38 resistant cell
lines, independently of these cell lines being de novo re-
sistant or having acquired resistance, and also irrespec-
tively of whether or not the cell lines expressed estrogen
receptor (Table 2 and Figs. 3 and 4). Two of these were
particularly evocative: BCRP/ABCG2 and ID3.
BCRP
We found mRNA and protein up-regulation of the xeno-
biotic drug transporter BCRP in the SN-38 resistant BC
lines. BCRP has previously been shown to transport
camptothecins [35] and to confer resistance to SN-38 in
colon cancer cell lines [5, 36] and non-small cell lung
cancer cells [37]. We found that BCRP was functionally
involved in resistance to SN-38 in our BC lines as inhib-
ition of BCRP reverted the resistance phenotype of the
SN-38 resistant BC cell lines, although the resistant
phenotype of MCF-7acq was only slightly re-sensitized
(Fig. 4). Thus, development of resistance may be multifac-
torial and clonal bias may also contribute to differences in
the specific molecular mechanisms for resistance to SN-
38. These data are consistent with results obtained with a
mouse model of BC that identified over-expression of
BCRP as an in vivo mechanism of resistance to topotecan
and showed that genetic ablation of BCRP increases sur-
vival of topotecan treated animals [38]. Similarly, in a
BCRP (−/−) mouse model with orthotopically trans-
planted BC tumor cells, co-treatment with topotecan and
the BCRP inhibitor Ko143 significantly increased survival
compared to topotecan monotheraphy [32]. These pre-
clinical data and the fact that BCRP is highly expressed in
aggressive breast cancer subtypes [39, 40] makes this drug
efflux transporter interesting as predictive biomarker and/
or as a therapeutic target.
ID3
ID proteins are helix-loop-helix (HLH) proteins that can
form heterodimers with other HLH proteins and inhibit
its interaction partner in binding to DNA. ID3 is in-
volved in tumor growth, invasiveness, metastasis, and
angiogenesis [41], and was up-regulated in the SN-38 re-
sistant BC cell lines (Additional file 1: Figure S10). This
is the first report to associate ID3 with resistance to SN-
38 and one possible explanation for this observation is
that negative regulation of DNA-binding by dimer part-
ners slows down cell cycle and results in increased num-
bers of cells in the G0/G1 phase - as we found in our
cell cycle analyses- which in turn will reduce sensitivity
to SN-38 (Additional file 1: Figure S5).
Taxanes are currently regarded as the most efficient
drug class in the management of BC and are commonly
used in neoadjuvant and adjuvant therapy of BC and in
management of mCB. In spite of showing overall response
rates of more than 40 %, patients progress in a relative
short time, and in many cases show cross-resistance to
second-line anthracyclines and subsequent regimens.
Interestingly, none of the SN-38 resistant cell lines had ac-
quired cross-resistance to docetaxel while both of the
MDA-MB-231 SN-38 resistant cell lines displayed minor
cross-resistance to the anthracycline epirubicin (Table 2).
It is quite intriguing that even in the MDAacq cell line,
which had a very strong up-regulation of the MDR1 pro-
tein, the cells retained sensitivity to docetaxel. Further-
more, our previously reported docetaxel resistant BC cell
lines showed cross-resistance to SN-38 (Additional file 1:
Figure S6). With an objective response rate of only 30 %
to irinotecan in docetaxel-refractory mBC, the present
preclinical results indicate that irinotecan could be admin-
istered prior to docetaxel to minimize cross-resistance be-
tween these two drugs. Although epirubicin is not
considered a substrate for BCRP, a recent study has shown
that high expression of BCRP correlated with resistance to
epirubicin in colorectal cancer cells [42] and this is con-
sistent with our findings in the SN-38 resistant MDA-
MB-231 cell lines with high BCRP expression. To try to
address the issue of cros-resistance, we included two novel
indenoisoquinoline Top-1 inhibitors, LMP400 and
LMP776, in this study, both of which are in early clinical
trials and are well-tolerated (https://clinicaltrials.gov/ct2/
show/NCT01051635, https://clinicaltrials.gov/ct2/show/
NCT01794104). Remarkably, LMP400 did not display
cross-resistance with SN-38 in three of the four SN-38 re-
sistant BC cell lines (Table 2), which may be explained by
the fact that LMP400 (NSC 724998) is not a substrate for
BCRP [5]. This suggests a therapeutic potential for
LMP400 in BC following disease recurrence upon irinote-
can treatment. In contrast, 3 of the 4 SN-38 resistant cell
lines were cross-resistant to LMP776 (Table 2).
Clearly, factors beyond ABCG2/BCRP may be involved
in resistance to SN-38. To address other possibilities we
explored other, known, molecular mechanisms under-
lying resistance to SN-38. In a panel of breast cancer cell
lines with varying levels of TOP1 CN, TOP1 mRNA,
Top1 protein and enzyme activity, we found consistency
between the TOP1 CN and protein levels (Additional file
1: Figure S2). Furthermore, higher TOP1 mRNA levels
were significantly associated with increased enzyme ac-
tivity and non-significantly associated to increased sensi-
tivity to SN-38, which is supported by other studies
using fewer cell lines [20, 26–29, 43, 44]. The level of
Top1 protein was reduced in the MDAacq, MCF-7acq
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and MDAde novo cell lines whereas only a minor decrease
was observed in the MCF-7de novo. These results recap-
itulate data from a BC mouse model of acquired topote-
can resistance that suggested reduced levels of Top1 as a
mechanism of in vivo resistance [38]. The mechanisms
causing reduced levels of Top1 protein remain elusive as
no changes were observed in the TOP1 CN or gene ex-
pression. However, this suggests that acquired resistance
to SN-38 might involve a decrease in Top1 protein
levels, which is also supported by studies demonstrating
a correlation between reduced Top1 levels and reduced
sensitivity to Top1 targeting drugs [45, 46]. The most
likely reason for these observations is that lower levels
of Top1 leads to reduction in the covalent-complex-
dependent double-strand breaks and thereby to reduced
cell death. However, reduced Top1 expression is prob-
ably only one among several resistance mechanisms to
SN-38, as the Top1 level only changed marginally in the
MCF-7de novo cell line. Consistently, a recent study sug-
gested elevated levels of Top1 as a predictive biomarker
for irinotecan response in MBC patients [47]. The Top1
protein may be modified by several PTMs including
phosphorylation [18, 30, 48], ubiquitination [49] and
SUMOylation [50]. These modifications of Top1 have
been associated to the response to Top1 targeting drugs
and we therefore compared differences in the Top1 iso-
electric patterns in the sensitive and resistant cell lines.
We identified a novel pattern of the Top1 isoelectric pat-
terns in the MDAacq cells, which may contribute to the
resistance to SN-38 (Fig. 3e).
Conclusion
In conclusion, molecular characterization of the developed
SN-38 resistant human BC cell line model system revealed
that acquisition of resistance to SN-38 in vitro is multifac-
torial and that acquired or de novo resistance share funda-
mental characteristics. In particular, up-regulation of the
BCRP drug efflux pump, low proliferation rates and down-
regulation of Top1 protein are suggested as key mediators
of SN-38 resistance in human breast cancer cell lines.
These preclinical observations should be clinically validated
in breast cancer biopsies derived from clinical studies in
which the patients were exposed to Top1 inhibitor treat-
ment to generate level 1 evidence for use of these markers.
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